Valuation : RAPT Therapeutics, Inc.

Market Cap 1.79B 1.54B 1.44B 1.32B 2.49B 171B 2.49B 17.07B 6.67B 86.36B 6.74B 6.59B 286B P/E 2025 *
-
P/E 2026 * -
Enterprise Value 1.79B 1.54B 1.44B 1.32B 2.49B 171B 2.49B 17.07B 6.67B 86.36B 6.74B 6.59B 286B EV / Sales 2025 *
-
EV / Sales 2026 * -
Free-Float
96.87%
Yield 2025 *
-
Yield 2026 * -
1 day+0.07%
6 months+0.10%
Current year+71.30%
Current year 29.77
Extreme 29.77
58.02
1 year 11.14
Extreme 11.145
58.02
3 years 5.67
Extreme 5.6652
218.8
5 years 5.67
Extreme 5.6652
325.92
10 years 5.67
Extreme 5.6652
409.68
Manager TitleAgeSince
President - 02/03/2026
Treasurer - 02/03/2026
Director TitleAgeSince
Director/Board Member - 02/03/2026
Director/Board Member - 02/03/2026
Date Insider Type Main position Quantity % Market Cap.
03/03/26 Tender

Director

51,762 0.1868%
03/03/26 Tender

Director

48,328 0.1744%
30/01/26 Free

Director

4,956 0.0179%
Change 5-day change 1-year change 3-year change Capi.($)
+0.07%-.--%+414.13%-61.81% 1.79B
+3.31%-3.70%+61.03%+103.64% 70.42B
+1.09%+3.40%+51.59%+93.39% 65.4B
-1.03%-1.52%+6.31%-5.28% 28.28B
-0.49%+5.43%+54.81%+13.87% 26.57B
-2.41%-7.09%-8.16%+455.82% 27.16B
+0.37%+0.70%+37.37%-15.78% 20.09B
+1.02%+6.43%+269.42%+420.34% 20.61B
+0.77%+0.19%+8.01%+520.34% 15.87B
-1.50%+1.60%+44.13%+151.30% 13.9B
Average +0.37%+1.06%+93.87%+167.58% 29.01B
Weighted average by Cap. +0.99%+0.72%+58.16%+153.76%

Financials

2025 *2026 *
Net sales - -
Net income - -
Net Debt - -
Logo RAPT Therapeutics, Inc.
RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapies for patients living with inflammatory and immunological diseases. Its lead drug candidate, RPT904, is a half-life extended monoclonal antibody (mAb) designed to bind free human immunoglobin E (IgE), which is being developing for the treatment of food allergy, chronic spontaneous urticaria (CSU) and potentially other inflammatory diseases. The Company’s oncology drug candidate, tivumecirnon, is an oral small-molecule C-C motif chemokine receptor 4 (CCR4) antagonist designed to selectively inhibit the migration of immunosuppressive regulatory T cells (Treg) into tumors.
Employees
60
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
A
  1. Stock Market
  2. Stocks
  3. RAPT Stock